Physician profile
Sanjay Sharma
NPI 1174609358
$668,210.66
in general payments reported to CMS, 2019-2025
79 companies · $74K in 2025
The $74K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $28K · 2021: $37K · 2022: $93K · 2023: $124K · 2024: $182K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $295K · Travel and Lodging: $42K · Consulting Fee: $26K · Food and Beverage: $16K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $295,084.73 |
| Travel and Lodging | $42,239.19 |
| Consulting Fee | $26,227.50 |
| Food and Beverage | $16,396.98 |
| Education | $172.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $133,198.89 | 2019-2025 | Bavencio |
| Astrazeneca Pharmaceuticals Lp | $111,119.23 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $85,248.87 | 2019-2025 | Opdivo, Opdualag, Camzyos |
| Regeneron Healthcare Solutions, INC. | $66,268.14 | 2019-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $55,965.84 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $50,817.38 | 2019-2025 | Kyprolis, Blincyto, Lumakras |
| Celgene Corporation | $40,565.00 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Genzyme Corporation | $39,331.68 | 2019-2025 | |
| Pfizer INC. | $24,139.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17,442.97 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
| Array Biopharma INC | $9,772.02 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $6,154.32 | 2019-2025 | Venclexta |
| Abbott Laboratories | $4,332.10 | 2019-2023 | Fortify Assura, Coroflow, Jot Dx |
| Lilly USA, LLC | $2,715.36 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Abiomed | $2,692.41 | 2019-2021 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $2,491.87 | 2021-2022 | |
| Janssen Biotech, INC. | $2,313.68 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Jazz Pharmaceuticals INC. | $1,967.25 | 2019-2024 | |
| Exelixis INC. | $1,595.09 | 2020-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $1,315.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,169.18 | 2019-2025 | |
| Eisai INC. | $868.84 | 2019-2025 | |
| Astellas Pharma US INC | $633.73 | 2019-2025 | Xtandi, Xospata, Padcev |
| Daiichi Sankyo INC. | $540.63 | 2020-2025 | Enhertu, Datroway |
| Incyte Corporation | $494.62 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Pharmacyclics LLC, An Abbvie Company | $474.88 | 2019-2023 | Imbruvica, Epkinly |
| Gilead Sciences, INC. | $473.30 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $398.16 | 2019-2025 | Tecentriq, Itovebi, Alecensa |
| Karyopharm Therapeutics INC. | $325.78 | 2021-2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.78 | 2019-2025 | Gilotrif |
| Seagen INC. | $259.54 | 2019-2023 | Adcetris, Tukysa |
| Ipsen Biopharmaceuticals, INC | $216.28 | 2019-2025 | Somatuline Depot, Onivyde |
| Janssen Pharmaceuticals, INC | $214.11 | 2020-2021 | |
| Blueprint Medicines Corporation | $213.71 | 2022-2025 | Ayvakit |
| Agios Pharmaceuticals, INC. | $151.34 | 2019-2025 | Pyrukynd |
| Alexion Pharmaceuticals, INC. | $129.57 | 2019-2024 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $123.65 | 2021-2025 | Qinlock, Tgct |
| Myovant Sciences INC. | $118.10 | 2021-2022 | |
| Caris Mpi, INC. | $114.76 | 2025 | Mi Cancer Seek |
| Comsort, INC | $100.00 | 2019 | |
| Coherus Oncology, INC. | $99.20 | 2022-2025 | Loqtorzi |
| Rigel Pharmaceuticals, INC. | $99.06 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Blue Earth Diagnostics | $87.00 | 2019-2021 | |
| Geron Corporation | $83.24 | 2024-2025 | Rytelo |
| Tesaro, INC. | $81.79 | 2019 | |
| Beigene USA, INC. | $81.42 | 2021-2024 | Brukinsa |
| Puma Biotechnology, INC. | $73.25 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $65.58 | 2019-2020 | |
| Verastem, INC. | $53.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $47.29 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $47.13 | 2025 | |
| Sobi, INC | $46.95 | 2024-2025 | |
| Medtronic, INC. | $40.05 | 2025 | Superlock |
| Dova Pharmaceuticals | $39.95 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $37.84 | 2024-2025 | Sylvant |
| Tg Therapeutics, INC. | $36.01 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $35.63 | 2019 | |
| Foundation Medicine, INC. | $33.82 | 2019 | |
| Genmab U.S., INC. | $32.32 | 2023 | Epkinly |
| Legend Biotech USA INC. | $28.48 | 2025 | Carvykti |
| Csl Behring | $25.86 | 2019 | |
| Springworks Therapeutics, INC. | $23.84 | 2024 | Ogsiveo |
| Tolmar, INC. | $23.49 | 2023 | |
| Shield Therapeutics INC | $22.77 | 2025 | |
| Morphosys, US INC. | $22.57 | 2023 | Monjuvi |
| Mirati Therapeutics, INC. | $21.70 | 2023 | Krazati |
| Beone Medicines USA, INC. | $21.39 | 2025 | Brukinsa |
| Clovis Oncology, INC. | $21.25 | 2019 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Kite Pharma, INC. | $19.34 | 2021 | |
| Epizyme, INC. | $18.26 | 2021 | |
| Taiho Oncology, INC. | $18.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.13 | 2019 | |
| Progenics Pharmaceuticals, INC. | $15.72 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.71 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.60 | 2019 | |
| Sirtex Medical INC | $7.46 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,032.46 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.